Navigation Links
ArunA Biomedical Names Harold Ingalls to its Board of Directors
Date:9/9/2008

ATHENS, Ga., Sept. 9 /PRNewswire/ -- ArunA Biomedical, Inc., the first company to commercialize human embryonic stem cell derived products and services, announced today the appointment of former Serologicals Corporation CFO, Harold "Bud" Ingalls, to its Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

Mr. Ingalls brings over 40 years of financial leadership, including nearly 20 years of experience as a chief financial officer to ArunA's Board. Prior to his current role as CFO of Premier Exhibitions, Mr. Ingalls served as Vice President and Chief Financial Officer at CardioMEMS, where he played a key role in the organization's transformation. During his tenure at CardioMEMS, Mr. Ingalls led the completion of two private financing rounds totaling over $45 million with venture capitalists and strategic investors. From 2001 to 2006, he held the position of Vice President of Finance and Chief Financial Officer of Serologicals Corporation. Under Mr. Ingalls' leadership, Serologicals' enterprise value increased by nearly $1.0 billion, as the result of strong organic growth, successful acquisitions and stringent cost control. Prior to his work with Serologicals, Mr. Ingalls was employed as President and Chief Financial Officer of LaRoche Industries, Inc. Mr. Ingalls is a member of the American Institute of Certified Public Accountants and received a BBA degree in Accounting from the University of Wisconsin.

"We are pleased to welcome Bud to the ArunA Board. His domain knowledge and impressive combination of strategic and financial expertise in the life sciences industry will be a tremendous asset to ArunA Biomedical as we move forward in our next phase of growth," said ArunA President and CEO, William T. Sharp.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.

For more information, visit: http://www.arunabiomedical.com


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
2. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
3. Creator of PubMed Central biomedical research database recognized for outstanding citizen service
4. Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion
5. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant
6. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
7. The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere
8. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
9. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education
11. Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: